Biogen (BIIB) Accounts Payables (2016 - 2025)
Historic Accounts Payables for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $432.0 million.
- Biogen's Accounts Payables rose 183.88% to $432.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $432.0 million, marking a year-over-year increase of 183.88%. This contributed to the annual value of $432.0 million for FY2025, which is 183.88% up from last year.
- Latest data reveals that Biogen reported Accounts Payables of $432.0 million as of Q4 2025, which was up 183.88% from $413.1 million recorded in Q3 2025.
- In the past 5 years, Biogen's Accounts Payables registered a high of $589.2 million during Q4 2021, and its lowest value of $354.5 million during Q2 2024.
- Its 5-year average for Accounts Payables is $427.2 million, with a median of $423.4 million in 2024.
- Its Accounts Payables has fluctuated over the past 5 years, first surged by 2952.3% in 2021, then crashed by 2121.34% in 2024.
- Biogen's Accounts Payables (Quarter) stood at $589.2 million in 2021, then fell by 16.58% to $491.5 million in 2022, then decreased by 17.95% to $403.3 million in 2023, then increased by 5.18% to $424.2 million in 2024, then rose by 1.84% to $432.0 million in 2025.
- Its Accounts Payables stands at $432.0 million for Q4 2025, versus $413.1 million for Q3 2025 and $408.4 million for Q2 2025.